The Galien Foundation Announces 2024 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Public Sector Innovation"
Articolo Precedente
Articolo Successivo
"As Chair of the Prix Galien UK Committee, I am proud to announce the exceptional candidates across five distinguished categories. These individuals and organisations embody the essence of healthcare excellence, demonstrating profound dedication to improving the human condition. Their remarkable contributions serve as beacons of hope and progress, shaping the future of healthcare for generations to come," said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee.
The award committee is reviewing what was innovative during the product's scientific development, application, or clinical utility, what was learned for the future of biomedical science from the product's introduction to the clinic, and what impact the product has had on human health.
"Each candidate stands as a testament to the relentless pursuit of health innovation and the enduring spirit of human achievement. We congratulate all individuals behind these life-changing products who have pledged their commitment to a healthier future for all," said Bruno Cohen, Chairman of The Galien Foundation.
The 2024 Prix Galien UK Award Candidates are as follows:
Best Biotechnology Product (Candidates)
Best Digital Health Solution (Candidates)
Best Medical Technology (Candidates)
Best Pharmaceutical Product (Candidates)
Best Public Sector Innovation (Candidates)
The Prix Galien UK Awards launched in 1990 and have been awarded to 51 products since its inception. Winners are selected every two years by the Prix Galien UK Awards Committee, which comprises 14 experts in the field, and includes a number of the UK's leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.
During the ceremony, the 2024 Prix Galien UK Lifetime Achievement Award will be bestowed upon Professor Sir John Bell, President, CEO of the Ellison Institute of Technology Oxford - Emeritus Regius Professor of Medicine, University of Oxford. Sir John will deliver the keynote address, "Supporting the life sciences industry in the UK."
Prix Galien UK Awards Committee 2024
Pr Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics
Committee Chair
Pr Jane ADAM
Honorary Professor, University of Exeter, Consultant Radiologist, St George's Hospital London and former Chair Technology appraisal committee, NICE
Pr Bruce CAMPBELL
Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor,
Exeter
Dr Stephanie KUKU
Chief Knowledge Officer, Conceivable Life Sciences, Senior Consultant, Hadrian Health, Board Member Equinox and Board Trustee, The Kings Fund
![The Galien Foundation Announces 2024 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Public Sector Innovation"](https://mma.prnewswire.com/media/2414480/GalienLogo_800x300_Logo.jpg)
Pr Sudhesh KUMAR
Vice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)
Pr Sir Robert LECHLER
Emeritus Senior Vice President (Health), King's College London
Pr Andrew MORRIS
Director, Health Data Research UK & Professor of Medicine and Vice Principal Data Science,
University of Edinburgh
Dame June RAINE
Chief Executive, Medicines and Healthcare products Regulatory Agency
Pr Duncan RICHARDS
Professor of Clinical Therapeutics, University of Oxford
Pr Liam SMEETH
Professor of Clinical Epidemiology and Director of the London School of Hygiene and Tropical Medicine
Pr Rosalind SMYTH
Professor of Child Health, UCL Great Ormond St. Institute of Child Health, Vice Dean Research in the UCL Faculty of Population Health Sciences & Vice President (Clinical) UK Academy of Medical Sciences
Dr Lauren WALKER
Senior Clinical Lecturer in Clinical Pharmacology & Therapeutics and Internal Medicine,
University of Liverpool
Pr Moira WHYTE
Sir John Crofton Professor of Respiratory Medicine,
University of Edinburgh
About The Galien Foundation
The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards programme dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
For more information, visit www.galienfoundation.org.
Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/
Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
[email protected]
+44 20 3217 7060
Media Contact (Global):
Kara Bradley
Finn Partners
[email protected]
646-213-7243
Logo - https://mma.prnewswire.com/media/2414480/GalienLogo_800x300_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-2024-prix-galien-uk-award-candidates-for-best-biotechnology-product-best-digital-health-solution-best-medical-technology-best-pharmaceutical-product-and-best-public-sector-innovation-302147180.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN16191&Transmission_Id=202405160400PR_NEWS_EURO_ND__EN16191&DateId=20240516)